On 27 October 2026, Beiersdorf published its third-quarter results, and the contrast within a single group is stark. According to the figures released by the company, the Derma division, driven by Eucerin and Aquaphor, grew 10.6% organically over the quarter, while NIVEA fell 4.9%. Over the first nine months of the year, group sales reached \u20ac7.3 billion, an organic decline of 2.8%, and the full-year guidance of a low-single-digit decline was confirmed.<\/p>\n
For the head of an SME, a mid-sized company or a cosmetics house, this result goes beyond a stock-market anecdote. It shows that the same consumer, in the same skincare market, no longer rewards the same promises: proof, specialisation and medical credibility are gaining ground while the generalist mass brand has to reinvent itself. It is a useful reading for any brand preparing its 2027 positioning.<\/p>\n
The very title of the 27 October release sums up the situation: growth at Derma and La Prairie is accelerating, while the NIVEA turnaround is “progressing”. That turnaround is part of an 18-month transformation plan the group announced with its half-year results in August 2026. Beiersdorf had then lowered its target for the year: from “flat to slightly growing”, it moved to a low-single-digit organic decline. The group confirmed this trajectory in October.<\/p>\n
The group explains NIVEA’s decline by trade tensions with some retailers and by stock reductions on their side, while saying that sales to consumers keep growing worldwide. According to the company, this is therefore a channel effect rather than a rejection of the brand. The explanation matters, but it remains the company’s own: it is an interpretation, not a fact established by a third party. The coming quarters will show whether the stock effect fades as announced.<\/p>\n
Meanwhile, another major player pointed to the strength of certain segments. Est\u00e9e Lauder published its fiscal 2027 first-quarter results on 2 November 2026: organic sales up 6%, with fragrance up 20%. Here again, it is the categories with a strong identity, more than the generalist offer, that drive growth.<\/p>\n
Dermocosmetics refers to skincare formulated and presented with a logic close to skin health: formulas targeting a specific concern (sensitive, atopic, pigmented or blemish-prone skin), frequent recommendation by healthcare professionals, and a promise backed by tolerance or efficacy studies. This definition is not regulatory: it is a market positioning, which is why very different brands claim it.<\/p>\n
This positioning protects revenue for three reasons. First, the buyer is less sensitive to promotions: they are looking for a solution to a specific need and rarely switch products as long as the result is there. Second, prescription (pharmacist, dermatologist, specialised beauty therapist) creates a recommendation that social media algorithms do not replace. Finally, the brand relies on a narrative of proof that lasts longer than the trend of the moment. The cost of this strategy is real: trials, studies, training of relays, selective distribution.<\/p>\n
It would nevertheless be wrong to conclude that the generalist is doomed. NIVEA remains one of the best-selling skincare brands in the world, and its current decline is, according to Beiersdorf, partly cyclical. The lesson is rather about the level of demand: a brand that differentiates itself neither through proof, nor through experience, nor through price must now justify its place on the shelf, quarter after quarter.<\/p>\n
The same market movement does not play out the same way depending on whether you run a founder-led brand, an SME or a group. Before committing budgets, it is useful to ask yourself the following questions for each profile.<\/p>\n
These questions do not have a universal answer, but they have the advantage of turning a financial headline into an action plan. An independent brand has neither the advertising budget of a global group nor its bargaining power with retailers; it compensates by being irreplaceable for a given use, audience or network of prescribers.<\/p>\n
Channel diversification deserves particular attention. A brand that makes most of its sales with a single retailer is exposed to a renegotiation, a stock reduction or a change of listing that it does not control. Gradually opening its own site, pharmacies, salons or export reduces this dependence, provided it is done at a pace that production, logistics and compliance in each market can sustain without degrading service quality.<\/p>\n
The question should also be looked at from the investor’s angle. In a market where growth is concentrated in a few segments, acquirers value brands with a loyal customer base, documented formulation and controlled distribution. This reading matches that of the beauty brand acquisitions that have multiplied this year, which make the strength of the file a component of value in its own right.<\/p>\n
At Clear, an EU \/ UK \/ US cosmetic regulatory compliance firm, we see every day what separates a credible promise from a fragile one. In our exchanges with the brands we support, the sticking point is rarely the formula itself: it is the gap between what marketing wants to claim and what the product file can actually demonstrate. The closer a positioning gets to skin health, the stronger this requirement for consistency.<\/p>\n
The good practices are simple to state. Build the promise from the available evidence rather than the other way around, review each claim before marketing materials go into production, anticipate destination markets from the design stage and keep the product file up to date. On that last point, cosmetic regulations<\/a> frame how a product may be presented, and a “derma” positioning is no exception: it authorises no medical claim and no promise of cure.<\/p>\n